Hormone Use After Nonserous Epithelial Ovarian Cancer

Power, Laura E.; Lefas, Georgia; Lambert, Pascal; Kim, Diane; Evaniuk, Debra; Lotocki, Robert; Dean, Erin; Nachtigal, Mark W.; Altman, Alon D.

doi:10.1097/aog.0000000000001396

Cited by 27 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two randomized trials as well as prospective and retrospective cohort and case-control studies have shown no adverse effect menopausal hormone therapy on survival in women who have been treated for ovarian cancer 49–55. They used a variety of regimens: estrogen alone or combined with a progestogen or testosterone.…”

Section: Introductionmentioning

confidence: 99%

“…A retrospective cohort study using the Manitoba Cancer Registry and Drug Program Information Network of 357 women found that use of menopausal hormone therapy (n=94) for non-serous epithelial ovarian cancer was not associated with harm and did not decrease overall or disease-free survival 55. It found that in menopausal hormone therapy users under 55 years of age, disease-free survival was longer but there was no statistical difference in overall survival for this age group.…”

Section: Introductionmentioning

confidence: 99%

“…With regard to endometrioid ovarian cancers , which are potentially estrogen-sensitive, menopausal hormone therapy does not appear to have adverse effects. However, while menopausal hormone therapy appears to be safe in early-stage disease, this may not be the case in women with more advanced cancers, who commonly have residual, potentially hormone-responsive disease after surgery 54 55. As there is no clear evidence of benefit of aromatase inhibitors in the treatment of clear cell and mucinous carcinomas , estrogen replacement is a reasonable option for patients who are at low risk of tumor recurrence, but initiating such therapy should be individualized.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis

Rees

Angioli

Coleman

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

Worldwide, it is estimated that about 1.3 million new gynecological cancer cases are diagnosed each year. For 2018, the predicted annual totals were cervix uteri 569 847, corpus uteri 382 069, ovary 295 414, vulva 44 235, and vagina 17 600. Treatments include hysterectomy with or without bilateral salpingo-oophorectomy, radiotherapy, and chemotherapy. These can result in loss of ovarian function and, in women under the age of 45 years, early menopause. The aim of this position statement is to set out an individualized approach to the management, with or without menopausal hormone therapy, of menopausal symptoms and the prevention and treatment of osteoporosis in women with gynecological cancer. Our methods comprised a literature review and consensus of expert opinion. The limited data suggest that women with low-grade, early-stage endometrial cancer may consider systemic or topical estrogens. However, menopausal hormone therapy may stimulate tumor growth in patients with more advanced disease, and non-hormonal approaches are recommended. Uterine sarcomas may be hormone dependent, and therefore estrogen and progesterone receptor testing should be undertaken to guide decisions as to whether menopausal hormone therapy or non-hormonal strategies should be used. The limited evidence available suggests that menopausal hormone therapy, either systemic or topical, does not appear to be associated with harm and does not decrease overall or disease-free survival in women with non-serous epithelial ovarian cancer and germ cell tumors. Caution is required with both systemic and topical menopausal hormone therapy in women with serous and granulosa cell tumors because of their hormone dependence, and non-hormonal options are recommended as initial therapy. There is no evidence to contraindicate the use of systemic or topical menopausal hormone therapy by women with cervical, vaginal, or vulvar cancer, as these tumors are not considered to be hormone dependent.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis

Rees

Angioli

Coleman

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer (OC) is the fth leading cause of cancer-related death among women in the world, which has the highest mortality rate of all gynecologic neoplasms (Galdiero et al 2015). Although remarkable advances in the surgery, chemotherapy and radiotherapy progress have been made, the overall OC survival rate has not improved in the past decades (Power et al 2016;Zhou et al 2017). Therefore, it's urgent to develop novel, evidence-based and safe approaches for its prevention and treatment.…”

Section: Introductionmentioning

confidence: 99%

Resveratrol Suppresses Ovarian Cancer Cell Growth and Invasion Through Upregulation of microRNA-34a

Wei

Yao

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

Resveratrol (RES), a natural compound found in red wine, has previously reported to suppress ovarian cancer (OC) cell growth in vitro and in vivo; however, its potential molecular mechanisms are not fully elucidated. The aim of this study is to investigate the suppressive potential of RES in OC cell growth and invasion and reveal the underlying mechanisms. Herein, we found that RES treatment obviously suppressed the proliferative and invasive capacities of OC cells, and elevated cell apoptosis in vitro. Subsequent microarray and qRT-PCR analysis further showed that microRNA-34a (miR-34a) was significantly increased by RES treatment. Moreover, the inhibitory effects of RES on OC cells were enhanced by miR-34a overexpression, whereas weakened by miR-34a inhibition in OC cells. Of note, Bcl-2, an anti-apoptotic gene, was identified as a direct target of miR-34a. Then, we revealed that RES decreased the expression of Bcl-2 in OC cells in a dose dependent manner. Furthermore, the anti-tumor effects of RES were abolished by overexpression of Bcl-2 in OC cells. Overall, these results demonstrated that RES exerts the anti-cancer effects on OC cells through the miR-34a/Bcl-2 axis.

show abstract

“…Ovarian cancer is the fifth most common cause of cancerassociated mortality in females worldwide, and 90% of cases of ovarian cancer are epithelial-derived malignancies (1). Although ovarian cancer has an improved response to chemotherapy, the prognosis of patients with ovarian cancer is not ideal clinically, with very low survival rate (2,3). Studies have indicated that clinical pathological parameters, including age, tumor stage, patient's body function and residual tumor volume, are independent predictors of the prognosis of ovarian cancer (1-3); however, for patients with similar status and treatments, their survival rates were not the same (4).…”

Section: Introductionmentioning

confidence: 99%

miR‑221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF

2018

View full text Add to dashboard Cite

To observe the expression of microRNA-221 (miR-221) in ovarian cancer tissues and its effect and associated mechanism on proliferation and apoptosis in the ovarian cancer SKOV3 cell line. The expression of miR-221 and B-cell lymphoma 2 modifying factor (BMF) mRNA in ovarian cancer and para-carcinoma tissues was detected by reverse transcription-quantitative polymerase chain reaction, the expression of BMF was detected by western blot. MicroRNA. org online predicted that BMF was the possible target gene of miR-221, and the regulatory association was validated by a dual-luciferase reporter gene assay. SKOV3 cells were divided into 8 transfection groups: Anti-miR-negative control (NC); anti-miR-221; phosphorylated internal ribosome entry site 2 (pIRES2)-blank, pIRES2-BMF, small interfering (si)-NC, si-BMF, anti-miR-221+si-BMF and anti-miR-221+pIRES2-BMF groups. Cell proliferation was detected by EdU staining flow cytometry. The effect of transfection on cell apoptosis was detected by Annexin V/PI double staining, and the activity of caspase-3 was detected by spectrophotometry. The effect of anti-miR-221 or pIRES2-BMF transfection on SKOV3 cell proliferation was detected by MTT assay and flow cytometry, and the effect on apoptosis was detected by the Annexin V/PI double staining. Compared with para-cancer tissues, the miR-221 expression was significantly upregulated (P<0.001), the BMF mRNA expression was significantly downregulated (P<0.001), and the expression of BMF proteins was significantly downregulated in the ovarian cancer tissues. Dual-luciferase reporter gene assay confirmed a targeted regulatory association between miR-221 and BMF. The anti-miR-221 or pIRES2-BMF transfection significantly upregulated BMF expression in SKOV3 cells, significantly decreased cell proliferation and significantly increased cell apoptosis. The overexpression of BMF may enhance the proapoptotic and proliferation-inhibition effect of anti-miR-221 on SKOV3 cells. The transfection of si-BMF significantly promoted cell proliferation, reduced cell apoptosis and attenuated the proapoptotic and proliferation-inhibition effect of anti-miR-221 on cells. The expression of miR-221 was significantly upregulated and the expression of BMF was significantly down-regulated in ovarian cancer tissues. The overexpression of miR-221 antagonized the apoptosis of ovarian cancer SKOV3 cell and promoted the cell proliferation by targeted inhibition of the expression of BMF, which may serve a role in the pathogenesis of ovarian cancer.

show abstract

Hormone Use After Nonserous Epithelial Ovarian Cancer

Abstract: After treatment for nonserous epithelial ovarian cancer, hormone therapy is not associated with decreased disease-free or overall survival.

Cited by 27 publications

References 28 publications

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis

Resveratrol Suppresses Ovarian Cancer Cell Growth and Invasion Through Upregulation of microRNA-34a

miR‑221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF

Contact Info

Product

Resources

About